Key Insights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

1 of 0 completed with results

Key Signals

1 with results0

2Total

P 1 (1)

P 2 (1)

Not Yet Recruiting1

Terminated1

Unknown1

Clinical Trials (3)

Showing 3 of 3 trials

5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas

Collagen Cross-Linking With Ultraviolet-A in Asymmetric Corneas

Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitizers: HAL and BF-200 ALA Versus MAL

Showing all 3 trials